Stock Report

Download full stock data and analysis for free Last Updated: 27-Aug-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Glenmark Pharmaceuticals Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: GLENMARK | BSE: 532296

₹2,460.00

up-down-arrow ₹21.70 (0.89%)

As on 27-Aug-2026IST

Market cap

info icon

₹69,307 Cr

Revenue (TTM)

info icon

₹17,737 Cr

P/E Ratio

info icon

38.5

P/B Ratio

info icon

6.3

Div. Yield

info icon

0.1 %

Edit peer-selector-edit
Glenmark Pharmaceuticals Laurus Labs Wockhardt Rubicon Research Piramal Pharma
Market cap (₹ Cr)
 69,307 1,03,940 31,878 30,554 28,624
Revenue (₹ Cr)
 17,737 7,270 3,564 1,936 9,205
Net Profit (₹ Cr)
 1,797.81 1,090.76 414.00 288.22 -371.81
Net Margin (%)
 9.86 14.89 11.23 14.79 -3.93
RoE (%)
 30.87 21.64 8.38 29.77 -3.85
Price to Earnings
 38.55 95.06 77.94 106.01 --
Price-To-Book
 6.32 18.43 6.33 22.76 3.58

Income Statement (₹ Cr)

Glenmark Pharmaceuticals Laurus Labs Wockhardt Rubicon Research Piramal Pharma
Operating Revenue arrow
17,736.55 7,269.64 3,564.00 1,935.80 9,205.28
Total Income arrow
18,236.50 7,323.34 3,686.00 1,948.58 9,449.59
Total Expenditure arrow
12,939.86 5,235.79 2,792.00 1,485.56 8,195.15
EBITDA arrow
4,796.69 2,033.85 772.00 450.24 1,010.13
Depreciation arrow
616.73 487.08 226.00 50.83 857.51
EBIT arrow
4,179.96 1,546.77 546.00 399.41 152.62
Interest arrow
204.50 161.45 217.00 40.84 342.73
Other Income arrow
499.94 53.70 122.00 12.78 244.31
Exceptional Items arrow
-1,942.85 0.00 12.00 0.00 -216.88
Profit before Tax arrow
2,532.56 1,439.02 463.00 371.35 -162.68
Provision for Tax arrow
734.75 348.26 49.00 83.14 209.13
Profit after Tax arrow
1,797.81 1,090.76 414.00 288.22 -371.81

Liabilities (₹ Cr)

Glenmark Pharmaceuticals Laurus Labs Wockhardt Rubicon Research Piramal Pharma
Shareholder's Funds arrow
10,512.11 5,300.06 4,940.00 1,288.82 8,162.62
Minority Interest arrow
0.10 2.84 -5.00 0.00 0.00
Non-Current Liabilities arrow
3,019.66 1,444.40 1,712.00 202.03 5,044.14
Current Liabilities arrow
6,376.43 3,635.43 1,622.00 835.87 4,758.28
Total Liabilities arrow
19,906.65 10,511.19 8,578.00 2,326.71 17,723.32

Assets (₹ Cr)

Glenmark Pharmaceuticals Laurus Labs Wockhardt Rubicon Research Piramal Pharma
Non-Current Assets arrow
7,567.18 5,220.48 5,343.00 519.60 10,211.52
Current Assets arrow
11,299.71 4,829.21 2,606.00 1,681.81 7,191.66
Total Assets arrow
19,906.65 10,511.19 8,578.00 2,326.71 17,723.32
Total Debt* arrow
0.00 2,397.49 2,125.00 259.37 5,495.48
Net Current Assets arrow
4,923.28 1,193.78 984.00 845.94 2,433.38
Contingent Liabilities arrow
787.81 420.55 768.26 19.09 95.72

Cashflow (₹ Cr)

Glenmark Pharmaceuticals Laurus Labs Wockhardt Rubicon Research Piramal Pharma
Cash From Operating Activities arrow
3,445.03 1,623.50 390.00 205.05 1,652.60
Cash Flow from Investing Activities arrow
-1,283.23 -1,088.66 -241.00 -409.72 -826.03
Cash from Financing Activities arrow
-2,708.75 -524.72 -54.00 283.07 -38.98
Net Cash Inflow / Outflow arrow
-546.95 10.12 95.00 78.39 787.59

Ratios

Profitability Ratios

 Glenmark Pharmaceuticals Laurus Labs Wockhardt Rubicon Research Piramal Pharma
ROCE (%) arrow
20.35 18.20 6.79 29.22 1.24
ROE (%) arrow
30.87 21.64 8.38 29.77 -3.85
ROA (%) arrow
10.00 10.99 4.94 24.77 -2.21
EBIT Margin (%) arrow
23.57 21.28 15.32 20.63 1.66
Net Margin (%) arrow
9.86 14.89 11.23 14.79 -3.93
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Glenmark Pharmaceuticals Laurus Labs Wockhardt Rubicon Research Piramal Pharma
Revenue Growth (%) arrow
32.94 22.62 18.37 46.65 0.78
EBIT Growth (%) arrow
126.49 87.41 252.26 62.13 -70.53
Net Profit Growth (%) arrow
138.48 116.73 377.85 89.49 -1,383.43
EPS Growth (%) arrow
174.53 114.66 1,001.33 78.60 -484.84
Book Value Growth (%) arrow
18.53 18.63 13.47 144.31 0.33

Valuation Ratios

 Glenmark Pharmaceuticals Laurus Labs Wockhardt Rubicon Research Piramal Pharma
Price / Earnings arrow
22.35 94.82 79.96 104.15 -91.09
Price / Book Value arrow
6.32 18.40 6.33 22.71 3.56
Dividend Yield (%) arrow
0.10 0.10 0.00 0.08 0.00
EV/EBITDA arrow
14.21 52.13 43.17 67.52 32.32
Market Cap (₹ Cr) arrow
60,201.30 53,545.31 19,071.62 12,753.19 18,108.89

Solvency Ratios

 Glenmark Pharmaceuticals Laurus Labs Wockhardt Rubicon Research Piramal Pharma
Debt to Equity arrow
0.00 0.12 0.31 0.11 0.53
Short term debt to equity ratio arrow
-- 0.28 0.09 0.05 0.09
Current Ratio arrow
1.77 1.33 1.61 2.01 1.51
Quick Ratio arrow
1.23 0.68 1.06 1.14 0.87
Interest Coverage arrow
13.38 9.91 3.13 10.09 0.53

Operating Efficiency Ratios

 Glenmark Pharmaceuticals Laurus Labs Wockhardt Rubicon Research Piramal Pharma
Debtors to sales (%) arrow
27.98 29.64 16.50 26.28 23.44
Asset Turnover arrow
0.99 0.73 0.43 1.66 0.55
Receivable days arrow
43.78 111.49 58.75 40.13 78.20
Inventory Days arrow
34.05 114.62 75.82 60.29 93.30
Payable days arrow
264.58 155.13 186.21 232.47 226.14
Cash Conversion Cycle arrow
-186.74 70.98 -51.64 -132.04 -54.64
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...